

OPEN

FOUNDATION

ANNUAL REPORT 2025



info@open-foundation.org



open-foundation.org



CONTENTS

Table of contents

—	A word from our director	3
—	Executive summary	4
I	About the OPEN Foundation	6
II	Key activities and impact	10
	ADEPT: Advanced Education in Psychedelic Therapy	11
	Foundations of Psychedelic Therapy	17
	OPEN Community	19
	ICPR 2026	24
	Writing and publications	26
	PsyPal	29
	Everything Else Matters	31
	Supporting the wider field	32
	Strategic advocacy and policy engagement	33
III	Acknowledgements	34
IV	Financial report	36
	A year of building	37
	Financial position	38
	1. Balance sheet as of 31 December 2025	39
	2. Income statement 2025	40
	3. Cash flow statement 2025	41
	4. Principles for valuation and determination of operating result	42
	5. Notes to the balance sheet	43
	6. Notes to the statement of income	46
	Approval of the financial statements	50
—	Looking forward	51

A word from our director

2025 was a defining year for the OPEN Foundation and for the field we serve.

It was a year in which European grounds slowly but unmistakably started to shift. Psilocybin became available for patients with treatment-resistant depression in Germany through the first compassionate use programme of its kind. Czechia approved a limited psilocybin access framework for severe mental disorders, while Norway became the first country to publicly reimburse generic ketamine for depression.

In the Netherlands the picture remained more complex. Even as scientific research and therapeutic applications advance, the path to formal regulation feels slow and unpredictable. While the first publicly funded clinical trial is slowly approaching, real momentum for political action is lacking. We will continue advocating for the Netherlands to follow its neighbours' leads and reclaim its position as a frontrunner in public health innovation.

That is why OPEN's role has expanded to strategic advocacy. Throughout 2025, we consulted with the United Nations Office on Drugs and Crime (UNODC), presented at the European Parliament, and supported mental health innovation frameworks with PAREA in Brussels.

During 2025, OPEN focused on preparing the ground for these very changes. In June, we celebrated our eighteenth anniversary — a milestone that felt like a true transition into organisational maturity. At the heart of this maturity is our vibrant Professional Community, which has become a platform where Europe's leading experts, clinicians, and researchers meet, exchange, and navigate this fast-moving field with ethics and care. Our team is larger than it has ever been, our operational ambitions are clear, and we are incredibly proud to have finally launched the inaugural cohorts of our brand-new educational initiatives: ADEPT Foundations and ADEPT, firmly solidifying professional education as a cornerstone of our mission.

Our other major initiatives are moving just as fast. Preparations for the seventh edition of the Interdisciplinary Conference on Psychedelic Research (ICPR 2026) progressed significantly throughout the year where we will welcome the global Psychedelics field community back to Haarlem, in the Netherlands.

None of this vital work would be possible without you. Whether you trained with us, joined our online community, attended our events, or are a board member: thank you. Your support matters deeply.



With gratitude,
Joost Breksema

EXECUTIVE SUMMARY

The year OPEN came of age

This was a year in which the OPEN Foundation came of age. Marking its eighteenth year, the Foundation turned long-held ambitions into tangible results across all four pillars of its work — education, scientific exchange, research, and public engagement and advocacy — while strengthening the team and systems that make such breadth possible.

Education saw the year's most visible transformation. OPEN's advanced therapist-training programme ADEPT welcomed its first cohort, and was joined by a second, complementary programme: Foundations of Psychedelic Therapy. This is a fully online introduction to the field, developed and launched this year with its own inaugural cohort. Together, the two now form a continuous learning pathway, carrying professionals from theoretical grounding through to advanced, practice-ready training, and establishing education and training as a cornerstone of OPEN's mission.

In scientific exchange, OPEN spent a year between conferences laying the groundwork for the return of the Interdisciplinary Conference on Psychedelic Research (ICPR), Europe's premier psychedelic research gathering, happening once every two years. Preparations for the seventh edition advanced on every front: a new visual identity, the opening of registration and the call for abstracts, the confirmation of leading speakers, and the planning of pre-conference workshops, building momentum towards next year's conference.

In research, the PsyPal project moved from preparation into practice. The first EU-funded clinical trial of psychedelic-assisted therapy, supported through Horizon Europe and uniting a 19-partner consortium across 9 countries, reached the milestone of its first patient dosing and began opening additional trial sites across Europe, a significant step towards evidence-based psychedelic care in palliative settings. Following the inclusion of the first trial patients, support group facilitators were successfully trained for sites in Prague, Copenhagen, Lisbon, and Groningen to offer peer support beyond the trial phase.

Throughout these initiatives, the project advanced its core focus: building cross-border connections and supporting the wider field with rigorous science, strong ethical frameworks, and clinical compassion.

OPEN's public engagement and advocacy were its broadest yet. At its heart was a rich community programme of 43 online and in-person events, supported by a growing membership and new formats such as the Psyche & Praxis Forum. The Foundation published 18 articles on its blog, contributed to the scholarly literature, and brought the PsyPal project to a wider audience through a public online panel. Plus, it premiered its documentary, *Everything Else Matters*, to its first audiences. And as a media and community partner, it lent its support to conferences, summits, and training initiatives across the field.

None of this would have been possible without OPEN's team, which grew in size and expertise, and the many volunteers whose dedication remains central to everything the Foundation achieves.

The year ahead is already in motion: ICPR returns for its seventh edition, both educational programmes prepare to welcome their second cohorts, and the PsyPal trial continues to progress. In each, OPEN builds on the foundations laid this year — and on its conviction that a stronger, more responsible field is built through rigorous science, sound ethics, and collective effort.

PART I

About the **OPEN** Foundation

Who we are

OPEN Foundation is a non-profit organisation based in Amsterdam, the Netherlands, that envisions a world where safe, beneficial, and accessible applications of psychedelics are ethically and responsibly integrated into science, healthcare, and society.

Founded in 2007, the OPEN Foundation is an independent, trusted organisation at the intersection of Europe's psychedelic research and therapy ecosystems. Working across disciplines, institutions, cultures, and sectors, OPEN drives collaboration, knowledge exchange, and ethical progress. The OPEN Foundation connects researchers, clinicians, patients, policymakers, and Indigenous voices within a growing international community dedicated to a responsible future for psychedelics.

OPEN's mission is to advance these therapies and research frameworks across Europe. It brings together and educates professionals, policymakers, and the public through its flagship conference, targeted educational programs, and collaborative research initiatives.

As a centre of expertise on psychedelic research and therapy, we provide communication, education, and training, developing and delivering leading programmes, including:

ICPR

Europe's premier psychedelic research conference, held every two years.

ADEPT

An advanced international training programme on psychedelic-assisted therapy for licensed mental health professionals.

ADEPT Foundations

A comprehensive online educational programme on psychedelic-assisted therapy for practitioners, clinicians and psychology-related graduate students.

Alongside these flagship initiatives, OPEN organises webinars, workshops, summer schools, community events, short courses, and other educational activities that support knowledge exchange and the responsible development of the psychedelic field.

These initiatives help shape the professional, scientific, and ethical standards needed for high-quality research and safe clinical practice.

Recognising the diversity of legitimate psychedelic use — medical, spiritual, personal, and other — OPEN promotes an inclusive approach that values the primacy of the subjective psychedelic experience. Drawing on its expertise and international network, OPEN helps ensure that the field develops with integrity, accessibility, and care.

This year, OPEN marked its eighteenth year of activity. The organisation continued to strengthen its internal infrastructure, refining its operating procedures and systems and expanding staff capacity to match a growing portfolio of activities, while remaining rooted in its founding values of independence, scientific rigour, integrity, collaboration, interdisciplinary approaches, and humanistic values.

Today, the OPEN Foundation serves as an independent centre of expertise committed to supporting the ethical, safe, and responsible integration of psychedelics into science, healthcare, and society. With nearly two decades of experience in education, research, and policy, OPEN now focuses its efforts on two high-impact areas: strategic advocacy and public engagement, and training and education.

Governance and organisational development

The OPEN Foundation is governed by an independent board, which oversees the organisation's strategic direction and ensures accountability across its finances and operations. The individual board members are all actively engaged in multidisciplinary psychedelic research themselves and play key roles in governance and thought leadership, particularly at the intersection of public communication, research, healthcare, and policy.

OPEN's executive leadership oversees strategic direction, operational management, and external partnerships, supported by a broader team spanning operations, education, marketing and communications, community building, professional events, and financial administration.

Board



Prof. em. Wim van den Brink
Chair



Erwin Krediet, MSc, PhDc.
Chair



Ass. prof. Michiel van Elk
Treasurer



Prof. dr. Patricia Pisters
Secretary



Renske Blom, MD PhDc.
Member

Operational team



Joost Breeksema, PhD
Executive Director



Timo Spijkers
Operational Director — left December 2025



Ana Martins
Operational Manager ICPR & ADEPT



Ray Yang
Operations & Project Manager



Iulia Rusu
Events & Membership Manager



Jasmine Virdi
Professional Events Coordinator



Daan Keiman
Education Lead, ADEPT



Nino Galvez
Marketing & Communications Manager
— departed in August 2025



Alexandra Bideaia
Marketing & Communications Manager
— joined in July 2025



Herman Kalter
Financial Controller — retired end of 2025



Ben van Arem
Financial Administrator



Aref Touleimat
Student Coordinator, ADEPT

Organisational maturity

While OPEN remains lean in size, the past year marked continued professionalisation across roles and systems. With clearer team structures, expanded internal expertise, and cross-functional collaboration now embedded in daily operations, the organisation is increasingly well positioned to manage multiple long-term initiatives simultaneously.

This maturation of internal capacity signals OPEN's readiness to scale its impact, while staying grounded in the values that have guided it since its founding: scientific integrity, critical inquiry, and responsible innovation.

PART II

Key activities **and impact**

ADEPT: Advanced Education in Psychedelic Therapy



After a full year spent designing the programme in 2024, building and expanding the curriculum, assembling the faculty, preparing its legal framework, and setting up an online learning environment, 2025 was the year ADEPT truly came to life. It marked OPEN's concrete answer to a problem it had identified clearly: as psychedelic-assisted therapy matures and approaches regulatory approval, Europe will face a growing bottleneck in the form of a shortage of trained, qualified professionals able to deliver these treatments safely and ethically. ADEPT was created to help close that gap and to lay the long-term educational foundation for responsible, evidence-based psychedelic therapy across the continent.

Built on OPEN's nearly two decades of work at the intersection of psychedelic science, policy, and education, ADEPT is a rigorous, two-year, part-time hybrid training programme. It combines online learning, in-person training, and immersive, experiential practicums conducted in legal settings. What's more, it is grounded in trauma-informed care, cultural humility, and patient-centred practice.

The curriculum: ten modules

- 1 Orientation, core competencies, and key concepts**
Introduces the programme's cyclical structure and the core principles, competencies, ethics, and legal considerations of psychedelic-assisted therapy.

- 2 Historical and critical perspectives on psychedelics and psychedelic-assisted therapy**
Traces the history and diversity of human psychedelic use and how it informs contemporary practice.

- 3 Neurobiology and psychopharmacology of psychedelics**
Covers pharmacology, neurobiology, and dosing, and how to integrate scientific evidence critically into clinical practice.

- 4 Clinical evidence: risks, processes, outcomes**
Examines therapeutic mechanisms, outcomes, risks, and adverse effects within integrative care frameworks.

- 5 Models, modalities, and paradigms of (psycho)therapy in PAT**
Applies diverse evidence-based therapeutic frameworks to preparation, session facilitation, and integration.

- 6 The arc of psychedelic-assisted therapy: preparation**
Focuses on screening, contraindications, informed consent, risk mitigation, and building the therapeutic alliance.

- 7 Understanding and working with non-ordinary states of consciousness**
Explores the personal, transpersonal, and interpersonal dimensions of non-ordinary states, including transference.

- 8 The arc of psychedelic-assisted therapy: session**
Covers supporting patients during sessions, managing intense experiences, aftercare, and therapist self-care.

- 9 The arc of psychedelic-assisted therapy: integration**
Addresses the integration phase and infrastructures for long-term, meaning-making care.

- 10 The science and art of group therapy with psychedelics**
Examines group dynamics, boundaries, safety, supervision, and ethical, inclusive practice.

Each module moves through ADEPT's signature four-part week-cycle of theory, practice, ethics, and integration. They draw on a transdisciplinary framework that spans psychotherapy, psychiatry, neuroscience, pharmacology, clinical research, Indigenous wisdom, anthropology, clinical chaplaincy, history, and philosophy.

Teaching combines on-demand recorded lectures with weekly live tutor groups led by qualified tutors, monthly live Q&A sessions with core and guest faculty, and curated supplementary readings and recordings, delivered through the Moodle learning environment, Zoom, and the Circle community platform. Students dedicate approximately five to eight hours each week, and those who complete the programme receive an educational certificate issued by the OPEN Foundation.

Teaching faculty

ADEPT's faculty was chosen for their extensive experience, diverse expertise, and leadership in psychedelic-assisted therapy, clinical research, ethics, and education.



Marc Aixalà, MSc

Licensed health psychologist, psychotherapist, and breathwork facilitator who coordinates support services at ICEERS.



Anja Loizaga-Velder, PhD

German-Mexican clinical psychologist and psychotherapist, co-founder of the Nierika Institute for Intercultural Medicine.



Genesee Herzberg, PsyD

Clinical psychologist and co-founder of Sage Integrative Health, Alchemy Community Therapy Center, and the International Alliance of MDMA Practitioners.



Roman Palitsky, PhD

Assistant Professor of Psychiatry at Emory University and Director of Research Projects in Spiritual Health.



Prof. Erika Dyck, PhD

Professor at the University of Saskatchewan and Canada Research Chair in the History of Health & Social Justice.



Iain Jordan, MB BCH BaO MSc MRCPI MRCPsych

Psychiatrist and educator with over 20 years' experience and 10 years as a senior lecturer at the University of Oxford. As clinical director of Clerkenwell Health, he oversaw over 100 psychedelic dosing sessions across 12 clinical trials.



Maria Papaspyrou, MSc

Integrative psychotherapist, supervisor, and family constellations facilitator. Co-director of the Institute of Psychedelic Therapy in the UK. She lives in Brighton, England.



Pat Song, PhD

Clinical psychologist, researcher, and educator practicing psychodynamic psychotherapy, and researching erotic transference/countertransference in psychedelic-assisted therapy.



Prof. Michiel van Elk, PhD

Associate Professor at Leiden University, leading the PRSM Lab, specialising in the cognitive neuroscience of altered states.



Rosalind Watts, PsyD

Clinical psychologist, founder of ACER Integration, and developer of the ACE model and the Watts Connectedness Scale.



Sara Oke, MS

Practitioner in psychedelic-assisted therapy and mental health futurist focused on how culture shapes the diagnosis and treatment of mental illness.



Bill Brennan, PhD

Psychologist and clinical researcher at Cybin Inc., co-developer of the EMBARK approach to psychedelic-assisted psychotherapy.



Michelle Glass, BA

Certified Level 3 IFS Practitioner and Oregon Licensed Psilocybin Facilitator.



Prof. Wim van den Brink, MD PhD

Emeritus Professor of Psychiatry and Addiction, Amsterdam Medical Center, University of Amsterdam. Scientific Director of the National Committee for Treatment of Heroin Addiction in Utrecht, the Netherlands.



Sergio Perez Rosal, MD

Physician and neuroscientist, board-certified in anesthesiology and emergency medicine. Adjunct Professor at the University of Ottawa.



Susana Bustos, PhD

Clinical psychologist and music therapist exploring entheogenic shamanic traditions and Western psychotherapy. She teaches at the California Institute of Integral Studies and serves as a subject matter expert for the Board of Psychedelic Medicines and Therapies.

Experiential practicums: psychedelic apprenticeship in practice

ADEPT includes three experiential practicums, held in legal, supervised settings in the Netherlands: one in Year 1 and two in Year 2. Across the progression, students move from experiencing altered states from the client's perspective to offering support one-to-one and then within a group, developing ethical discernment, clear boundaries, and relational attunement. Participation is mandatory; the use of any substance is optional.

YEAR 1

The 3-Day Experiential: an embodied introduction working with psilocybin truffles in a supported group setting, coming to know the client's experience from the inside.

YEAR 2

The 5-Day Individual Experiential: giving and receiving support one-to-one under close supervision, with extensive day-after feedback.

YEAR 2

The 5-Day Group Experiential: supervised facilitation practice in a group, navigating dynamics, boundaries, and shared experience.

Cohort 1's first practicum took place from 23 to 25 January 2026 at The Place to Be, a retreat centre near Zelhem, with preparation and integration sessions framing the experience. Their two five-day practicums follow in August 2026 and February 2027. The experiential was held by an experienced facilitation team:

Helena Aicher — Lead Facilitator

Elena Riede — Co-Facilitator

Dorien Tatalas — Co-Facilitator

Bay Deane — Co-Facilitator

Ana Martins — Experiential Logistics Manager

Martin Angerbauer — Lead Facilitator

Macha Godes — Co-Facilitator

Max Wolff — Co-Facilitator

Jorik Louws — Co-Facilitator

Aref Touleimat — Retreat Assistant



In-person training days

The cohort gathers for full-day, in-person training days at De Meditatietuin in Amsterdam's Amstelpark. These days are where the programme's relational and ethical skills become embodied: rather than studying the difficult states a facilitator must hold, students practise working with them directly, through group exploration, live demonstration, role play, and containment exercises. Each day pairs a charged therapeutic theme with a way of working through the body, led by an expert in the field:

Marc Aixalà, MSc — Community Building & Breathwork

Establishes the cohort as a working group and introduces breathwork as a route into non-ordinary states.

Tijmen Bostoen, MD — Exploring Fear and Touch (7 November 2025)

Practising how to meet fear and anxiety in a session, and how to offer supportive touch and its alternatives safely.

Aumer van Reemst, MSc — Movement and Anger (11 April 2026)

Using movement and music to work with anger and strong activation, and to contain it.

Pat Song, PhD — Erotic Transference and Boundaries (3 July 2026)

A psychodynamic framework for recognising erotic transference and countertransference, spotting red-flag behaviours, and reducing the risk of boundary violations.

TBD — Working with Critical Situations (16 January 2027)

Preparing students to recognise and respond to acute, high-risk moments in a session, reinforced by follow-up supervision.

Supervision

Furthermore, the cohort has access to ten supervision meetings conducted and guided by two clinical supervisors:

Shiva Thorsell, MSc — Clinical psychologist with over 25 years of experience and co-founder of the Senz mental health clinic, which offers ketamine-assisted psychotherapy as part of their treatment offerings, in the Netherlands.

Tijmen Bostoen, MD — Psychiatrist and researcher at ARQ Centrum '45 and Leiden University Medical Center, and Principal Investigator in clinical trials on MDMA-assisted therapy for patients with PTSD.

Advisory Council

An Advisory Council oversees curriculum development and quality assurance:

Robert Schoevers, MD, PhD — Professor of Psychiatry and Head of Department at the University Medical Centre Groningen.

Janis Phelps, PhD — Founder and director of the psychedelic therapy education programme at CIIS in San Francisco.

Lisa Bright, BSc — Senior adviser with decades of experience in executive board roles, strategy, and fundraising.

Holly Fernandez Lynch, JD, MBE — Associate Professor of Medical Ethics and Law at the University of Pennsylvania.

Programme team

The programme is delivered by the OPEN Foundation team:

Joost Breeksema, PhD — Director, OPEN Foundation.

Ana Martins, MSc — Operational Manager.

Daan Keiman, MA — Educational Lead and Tutor Group Leader.

Jasmine Viridi, MA and Johanna Hilla Sopanen, MSc — Tutor Group Leaders.

Aref Touleimat, BSc — Student Coordinator.

The programme is registered with the CRKBO (Centraal Register Kort Beroepsonderwijs), the Dutch registry for recognised providers of professional education. This registration confirms that ADEPT meets established quality standards for vocational training and continuing professional development. It also means its fees are exempt from VAT.

How ADEPT developed

On 1 May 2025, ADEPT welcomed its first cohort, with 18 students joining the inaugural group. The cohort was kept deliberately small so that learning could remain close, relational, and well supervised throughout the two years.

With the first cohort now well into their training, OPEN has turned to the next generation of practitioners.

In its first year of operation, ADEPT moved from a carefully designed blueprint to a living programme: a first cohort in the room and a second already on the way. But ADEPT is doing more than addressing a future gap in the workforce; it is helping to set the standard of care for a new era of mental health treatment, but it is also about creating a community of value-aligned, well trained professionals that represent the vanguard of practitioners, trainers, and supervisors leading the implementation of psychedelic-assisted therapy into real-world healthcare systems.

Foundations of Psychedelic Therapy

Also developed in parallel in 2025, Foundations of Psychedelic Therapy is OPEN's second educational programme, complementing the advanced training delivered through ADEPT. Where ADEPT prepares licensed mental health professionals for supervised clinical practice, Foundations provides the theoretical grounding that precedes it: a rigorous, evidence-informed introduction to the science, history, ethics, and clinical frameworks of psychedelic-assisted therapy.

The programme is delivered entirely online over thirteen months, in small, interactive cohorts that can be joined from anywhere in the world without the need to travel. This online format, together with a broader set of admission criteria, is what distinguishes Foundations from ADEPT.

Rather than requiring a clinical licence, Foundations is open to professionals with a background in mental healthcare who hold at least a BA or BSc in a mental health-related field and can demonstrate comprehension of academic English. Prospective students typically include psychologists and psychotherapists, medical doctors, nurses, and other professionals such as spiritual caregivers, clinical chaplains, and social workers.

As in ADEPT, the curriculum is organised around ten expert-led modules covering theory, practice, ethics, and integration, moving from the history and neuropharmacology of psychedelics, through clinical evidence, therapeutic models, and the arc of preparation, session support, and integration, to non-ordinary states of consciousness and the practice of group therapy.

Rather than focusing on a single substance, Foundations takes a trans-drug approach, teaching principles that apply across compounds while looking in depth at psilocybin, MDMA, (es)ketamine, and LSD, and drawing on ayahuasca and iboga to broaden the picture.

Teaching combines on-demand recorded lectures with weekly live tutor groups led by qualified tutors, monthly live Q&A sessions with core and guest faculty, and curated supplementary readings and recordings, delivered through the Moodle learning environment, Zoom, and the Circle community platform. Students dedicate approximately five to eight hours each week, and those who complete the programme receive an educational certificate issued by the OPEN Foundation.

Successful completion of Foundations counts as partial accreditation towards ADEPT, so that together the two programmes form a single learning pathway supporting professional development from early orientation to advanced, practice-ready expertise.

The first cohort began its journey in November 2025. In keeping with OPEN's mission as a non-profit committed to accessibility, multiple scholarships were awarded to support participation in

this inaugural cohort, prioritising applicants from underrepresented groups and those with financial needs.

With the first Foundations group now underway, OPEN have confirmed a second cohort to start in the Autumn of 2026. To support it, we will host a series of free events and OPEN Office Hours throughout the year. These are informal, interactive sessions where prospective students can meet the team, explore the curriculum and admission criteria, and decide whether the programme suits them before applying.



II · KEY ACTIVITIES AND IMPACT

OPEN Community

The OPEN Community serves as OPEN's year-round platform for connection, learning, and interdisciplinary exchange. Bringing together researchers, clinicians, therapists, students, policymakers, and engaged members of the public, it provides an ongoing space for dialogue across the rapidly evolving psychedelic field.

Through online and in-person events, journal clubs, expert talks, professional forums, local meetups, and peer-to-peer discussions, the community supports continuous learning and meaningful collaboration. It enables members to stay informed about scientific developments, connect across disciplines, and engage with emerging questions in research, therapy, policy, and culture.

In 2025, the community continued to grow, reaching a combined membership of 295 people across the OPEN and Professional tiers. Over the course of the year, members participated in 43 events, including lectures, discussions, journal clubs, local gatherings, and specialised professional programming. Together, these activities strengthened OPEN's role as a trusted convening space for the European psychedelic field.

By the numbers

295

People across the OPEN and Professional tiers. Membership remained constant over the course of 2025

+50%

Professional Membership grew by 50% over the course of 2025

43

Events in total, averaging roughly 3 per month, up from 2 per month in 2024 — 37 online, 6 in person



A programme of range and depth

A defining feature of 2025 was the programme's range and its coherence.

Sessions spanned rigorous science (neuroplasticity, women's health, chronic illness), altered states (microdosing, breathwork), clinical and therapeutic practice (IFS, EMDR, ACT, Jungian therapy), Indigenous and traditional knowledge (the Native American Church, Amazonian dieta, Icaros in Ayahuasca ceremonies), and the ethical edges of the field (psychological crises, sexual flourishing, abuse and misconduct).

Recurring strands gave the year its shape: the multi-part Psychedelics & Music series, the ongoing Autism and Psychedelics conversation, the cross-disciplinary Bridging Approaches sessions, and a steady rhythm of community gatherings, forming a series of ongoing conversations about psychedelic science.

Events in 2025

22 Jan	OPEN	Crafting Music for Altered States and Psychedelic Spaces — Krishna-Trevor Oswalt (East Forest), Xóchitl Ashe, Andrea Drury (ANILAH), and Liz Hanna
5 Feb	OPEN	The Gaps of Knowledge: Women, Embodiment, and Perception in Psychedelic Research — Julia Mandoki
11 Feb	PRO	Psychedelics and Neuroplasticity: Mechanisms of Lasting Change — Manesh Girn, PhD
13 Feb	OPEN	The Interplay of Music and Psychedelics — Katarina Jerotic
27 Feb	PRO	The Role of Music in Psychedelic-Assisted Therapy — Mendel Kaelen, PhD, Catharina Messell, MA, Frederick Streeter Barrett, PhD, moderated by Jasmine Virdi
20 Mar	PRO	Working with Erotic Feelings in Psychedelic-assisted Therapy: A Psychodynamic Framework — Pat Song, PhD
22 Mar	IN PERSON	Reconciling the Resurgence: Psychedelics and the Native American Church — Erika Dyck, PhD, Reanne Daniels, Kelly Daniels
26 Mar	PRO	Professional Member Mixer
1 Apr	PRO	Exploring the Therapeutic Potential of Ayahuasca-Assisted Psychotherapy in Grief — Débora González, PhD, with Karen Llewelyn
7 Apr	PRO	Exploring the Foundations & Future of Psychedelic-Assisted EMDR Therapy — Jocelyn Rose
10 Apr	OPEN	Ritual, Master Plants and Dieta: Altered States of Consciousness in Amazonia — Rebekah Senanayake
16 Apr	OPEN	OPEN Community Office Hour
17 Apr	IN PERSON	Music for Mushrooms by East Forest: Local Film Screening, Amsterdam
23 Apr	OPEN	Online Community Meet-up — Leor Roseman
13 May	PRO	An Introduction to Internal Family Systems in Psychedelic Therapy — Michelle Glass
19 May	FREE	Autism and Psychedelics — Alicia Danforth, Nick Walker, moderated by Daan Keiman, MA

20 May	OPEN	Bridging Approaches: Metaphysics — Peter Sjöstedt-Hughes, PhD, Michiel van Elk, PhD, Erika Salazar, Marta Santuccio, PhD
26 May	OPEN	OPEN Community Office Hour
28 May	IN PERSON	Local Community Meet-up, Amsterdam
29 May	OPEN	Icaros and Healing in Ayahuasca Ceremonies — Susana Bustos, PhD
5 Jun	OPEN	Group Psychedelic Integration: Processes, Peer Support & Community Care — Ian Roullier, Leonie Schneider, Tyler McPhee, Nadav Liam Modlin, PhD
17 Jun	PRO	Professional Member Mixer
26 Jun	PRO	Online Community Meet-Up — Janis Phelps, PhD
17 Jul	PRO	Psycholytic Therapy: Lessons from Low-Moderate Dose Psilocybin Research — Sara Reed
23 Jul	IN PERSON	Local Community Meet-up, Amsterdam
29 Jul	OPEN	How Can Psychedelics Become Reimbursed Care? — Floris Wolswijk
6 Aug	FREE	Autism and Psychedelics: A Continuing Conversation — Nick Walker, Daan Keiman, MA
14 Aug	PRO	Jungian Perspectives in Psychedelic-Assisted Therapy — Maria Papaspyrou
18 Aug	OPEN	OPEN Community Office Hour
9 Sep	OPEN	Microdosing Results, Limitations, & Emerging Questions — Jim Fadiman, PhD
15 Sep	PRO	Psychedelics and Acceptance and Commitment Therapy (ACT): A Process-Based Approach — Jason Luoma, PhD
17 Sep	IN PERSON	Local Community Meet-up, Amsterdam
23 Sep	OPEN	Breath and Body: Scientific and Experiential Perspectives on Breathwork — Guy William Fincham, PhD
25 Sep	FREE	Psychedelics & Infection-Associated Chronic Illness (IACI): Research and Emerging Insights — Albert Garcia-Romeu, PhD, Lukas Bobak, MD, Court Wing, Magalí Brecke, LAc, MaryAnn Welke Lesage
1 Oct	OPEN	Bridging Approaches: Phenomenology — Andy Letcher, PhD, Julian Kiverstein, PhD, Rebekah Senanayake, Eirini Ketzitidou Argyri
8 Oct	PRO	Breaking Open: Navigating Psychedelic-Induced Psychological Crises — Tim Read, MD
14 Oct	PRO	Embrace Pleasure: Supporting Sexual Flourishing Through Psychedelic Experience — Dee Dee Goldpaugh, LCSW
23 Oct	OPEN	Women and Psychedelics: Cycles, Care, and Conditions — Eline Haijen, PhD, Julia Mandoki, Grace Blest-Hopley, PhD, Mikaela de la Myco, moderated by Jennifer Chesak
27 Oct	OPEN	Psychedelics in Palliative Care: Clinical and Ethical Considerations — Rohini Kanniganti, MD, Anthony P. Bossis, PhD, Sunil Aggarwal, MD, PhD
29 Oct	OPEN	Psychedelic Listening: A Guided Music Journey with Wavepaths — Mendel Kaelen, PhD
13 Nov	IN PERSON	Local Community Meet-up, Amsterdam
20 Nov	OPEN	Understanding the Ibogaine and Iboga Landscape — Juliana Mulligan, LMSW
10 Dec	PRO	Psyche & Praxis Forum: Sexual Abuse and Misconduct in Psychedelic Therapy — Jasmine Virdi

A supervision & study group: erotic transference & countertransference

Alongside the regular events programme, October 2025 saw the OPEN Professional Community host a more intensive, small-group offering: a six-session supervision and study group on erotic transference and countertransference (T/CT) in psychedelic-assisted therapy, led by clinical psychologist Pat Song, PhD.

Transference and countertransference sit at the heart of effective psychotherapy, and in psychedelic-assisted therapy, these dynamics can become especially amplified and complex. Erotic T/CT in particular are among the most challenging and least openly discussed of these. They represent powerful relational states that, handled skillfully, can open the way to deep healing, but that risk causing harm if mismanaged. The group was created to provide practitioners with a rare, structured space to engage directly with this material.

This group was designed as an interactive, collaborative cohort for clinicians, guides, and researchers. Across the six weekly sessions, participants worked through case studies and foundational psychodynamic theory — containment, defenses, projective identification, and the therapeutic frame — and were invited to present their own clinical material for reflection and feedback in a supportive setting.

The arc of the programme drew on the stages of clinical mastery described by psychotherapist Nancy A. Bridges, moving the group from a concrete, external focus towards a more nuanced, internal understanding of how erotic feelings express deeper, often nonsexual, needs, and how to work with them ethically. A particular emphasis was placed on recognising red-flag behaviours and reducing the risk of boundary violations, skills with direct relevance to safety and ethics in the field.

The group was kept intentionally small to allow for the depth, safety, and intimacy the subject demands. In 2025, 8 practitioners took part in the supervision & study group.

A new forum for professional dialogue

In December 2025, the Professional Membership launched the dedicated Psyche & Praxis Forum, a new recurring series created to make space for ethical and professional dialogue within the field.

The inaugural session addressed sexual abuse and therapist misconduct in psychedelic-assisted therapy, setting the tone for a forum intended to engage openly and rigorously with some of the most difficult and important questions facing the profession.

A new collaboration: GLG

In October 2025, the OPEN Community began a collaboration with GLG, a firm that operates one of the largest global networks of subject-matter experts and connects organisations with those experts to help answer strategic questions. Through GLG's social-impact programme, the OPEN Foundation was given access to a dedicated research project, with the opportunity to consult up to five experts in hour-long sessions on a topic of our choosing.

OPEN framed the project around a question central to our work: how can we best grow our digital communities and deepen engagement within them? To support this, GLG drew on its network to identify experts with a proven track record of building and growing communities for large organisations and NGOs.

The collaboration offered a valuable opportunity to bring outside-in expertise into our planning and to think more strategically about community growth and engagement heading into the coming year.

The hands behind the OPEN Community

This year, the online programming work was supported by a dedicated group of volunteers who contributed their time, expertise, and enthusiasm across several initiatives.

For event programming and research, we worked closely with Annabelle Abraham, Courtney Zapor, Emma Uhlenhopp, and Malena Donas. Together, we tracked developments in psychedelic research and translated them into meaningful programming for our community. A highlight of this collaboration was the development of the Psychedelics & Music series, which brought together a deep listening event, a panel discussion on the role of music in psychedelic-assisted psychotherapy, and a presentation exploring the significance of Icaros in Ayahuasca ceremonies.

The monthly Journal Club sessions were coordinated by Bas Minnema, Gala Farah, and Steven Beck, who took ownership of this programme and ensured its consistent delivery throughout the year. Administrative support and community care for the online space were provided by Fiona Klaassen, whose work helped keep the day-to-day running of our online community smooth and welcoming.

We are incredibly grateful to all these volunteers for their commitment and the quality they brought to our work together.

ICPR 2026



The Interdisciplinary Conference on Psychedelic Research (ICPR) is Europe's premier scientific conference on psychedelic research and therapy. This is our flagship conference, and we have organised it once every two years since 2010.

ICPR brings together researchers, clinicians, therapists, policymakers, and members of the public and shares the latest in psychology, psychiatry, neuroscience, clinical practice, anthropology, ethnobotany, philosophy, policy, and more. It is the forum where science, practice, and policy meet, with a consistent emphasis on rigour, integrity, and real-world impact rather than hype.

Much of 2025's work went into preparing and launching the seventh edition of ICPR, which is planned to return to the PHIL in Haarlem, the Netherlands, from 4 to 6 June 2026.

Preparations ramped up in August 2025, when we launched the call for volunteers, inviting people to join the team and help shape the conference while gaining experience, expanding their networks, and contributing to a cause they care about. Volunteers were welcomed across six teams: Operations & Conference Management, Conference Programming, Marketing & Communications, Design, Sponsor & Partnership, and Website.

Tickets went on private sale in September 2025 for the OPEN community. In October 2025, we launched the early-bird tickets, giving everyone the chance to secure the best rate well ahead of the conference. Student, Regular, and Professional tickets were made available.

In November 2025, we launched the call for abstracts for ICPR 2026, inviting researchers, clinicians, scholars, and practitioners to help shape the conference programme. The call welcomed rigorous, ethical, and impactful work from across psychedelic science and therapy, with a submission deadline of 31 January 2026.

Reflecting ICPR's interdisciplinary character, submissions are encouraged from a broad spread of fields, including the humanities, arts, philosophy, and religious studies; social sciences and anthropology; psychology, psychotherapy, and psychiatry; neuroscience, pharmacology, and the natural sciences; and clinical research, medicine, economics, law, and regulatory science. Contributors can present in the format that best suits their work: an oral presentation, a panel discussion, a symposium, or a poster presentation.

A particular focus this year was the conference's look, feel, and digital home. We collaborated closely with designers to develop a distinctive new visual identity for this edition of ICPR, giving the 2026 conference a fresh, cohesive, and consistent brand. Alongside this, we started upgrading the conference website, creating a smoother experience for browsing the programme, exploring speaker profiles, and completing registration.

The 2026 programme is expected to feature more than 100 speakers, with an early confirmed line-up that includes Grace Blest-Hopley, PhD, Peter Gasser, MD, Anne Wagner, PhD, Joanna Kempner, PhD, and emeritus professor of psychopharmacology Harriet de Wit, PhD.

Pre-conference workshops — 3 June 2026

Ahead of the main conference, three full-day, in-person workshops will take place on 3 June 2026, designed for clinicians, researchers, practitioners, and members of the public who want to move beyond theory:

Psychedelics, Peace Building & Collective Liberation with the Ripples Collective

MDMA-Assisted Therapy for Couples with Dr. Anne Wagner

Psychedelics, Grief & End-of-Life Care with Dr. Houman Farzin and Dr. Débora González

With the visual identity refreshed, the website upgraded, registration open, and the call for abstracts underway by the end of December, the foundations for ICPR 2026 were firmly laid. As we head into 2026, the upcoming months will see the final programme take shape as abstracts are reviewed and the full line-up is confirmed.

We look forward to welcoming the global psychedelic research and therapy community back to Haarlem this coming June 2026 for what promises to be a landmark edition, with three days of rigorous, interdisciplinary exchange that continues to move ideas from the lab to the clinic and into society.

The groundwork laid this year reflects our wider commitment to growing ICPR as Europe's flagship gathering for the field, and to doing so with the care, quality, and integrity that define it.

Writing & publications

Psychedelic science moves quickly, and much of it stays locked inside journals and jargon. A core part of OPEN's educational work is translation: turning new research, shifting policy, and hard ethical questions into writing that a curious non-specialist can actually follow. Throughout 2025, our blog did exactly that.

Across the year, we published 18 articles. They ranged widely: plain-language reviews of the latest science (psilocybin and neuroplasticity, DMT and brain recovery, the emerging field of non-hallucinogenic psychedelics), explainers on the policy shifts reshaping the field in Europe (Germany's compassionate-use programme, the PsychedeliCare citizens' initiative), reflections from practitioners working on the ground (our "From the Field" series), milestone news from our own research (the first patient included in the PsyPal trial), an open letter on accountability and inclusion in the field, and a tribute to a pioneer the community lost. Read together, they offer a snapshot of a year in psychedelic science and care, and an open door for anyone wanting to understand it.

A few names recur through the year: Annabelle Abraham, Dilara Oexemann, Bárbara Messias, Leonie Staas, and Sergio Lázaro Martínez all contributed multiple pieces, and we're grateful for the time and care they gave to making this work accessible.



2025 articles

15 Jan	Music in Psychedelic Practices (From the Field) — Annabelle Abraham
20 Feb	Psychedelics and Nature (From the Field) — Annabelle Abraham
28 Mar	An Open Letter Reply to Dr. Stan Grof — Alex Belser, PhD; Andrea Ens, PhD; Bill Brennan, PhD; Dee Dee Goldpaugh, LCSW; Jeffrey Guss, MD
1 Apr	Psychedelics and Autonomy (From the Field) — Annabelle Abraham
1 Apr	Affect and Psychedelic Therapy: From Raw Emotion to Narrative Memory — Dilara Oexemann
7 Apr	The Global Psychedelic Survey 2025: A Study of International Naturalistic Psychedelic Use — OPEN Foundation
7 Apr	Who Benefits from the Psychedelic Renaissance? — Bárbara Messias
8 May	Psilocybin and Neuroplasticity: A Review of Preclinical and Clinical Studies — Sogol Fereydouni
14 May	Safe and Beneficial Psychedelic Experiences (From the Field) — Annabelle Abraham
19 May	PsychedeliCare: A European Citizens' Initiative for the Mind — Bárbara Messias
2 Jun	In Memory of Amanda Feilding (1942–2025): Honouring a Psychedelic Pioneer — OPEN Foundation
16 Jun	Psychedelics for Planetary Action: Unlocking an Overlooked Potential (Part 1) — Leonie Staas
1 Jul	Psychedelics for Planetary Action: Unlocking an Overlooked Potential (Part 2) — Leonie Staas
14 Jul	Psychedelics and Long COVID — Dilara Oexemann
6 Aug	Germany's Landmark Compassionate Use Programme for Psilocybin: A New Wave for Psychedelic Medicine in Europe — OPEN Foundation
11 Aug	First Patient Included Marks Major Milestone in EU-Funded Clinical Trial — OPEN Foundation
29 Oct	DMT Enhances Brain Recovery After Stroke: A New Frontier for "The Spirit Molecule" — Sergio Lázaro Martínez
3 Dec	The Promise of Non-Hallucinogenic Psychedelics: A Field Coming Into Focus — Sergio Lázaro Martínez

Contributions to the scholarly literature

Beyond the blog, OPEN's team and faculty contributed to the peer-reviewed and scholarly literature in 2025.

OPEN's Executive Director, Joost Breeksema and ADEPT faculty members Michiel van Elk, and Marc Aixalà were among the roughly thirty psychedelic researchers who co-authored a consensus paper identifying critical gaps in our understanding of psychedelic harm and safety. Drawing on a survey of the field's researchers, the paper sets out where our knowledge of risk falls short and proposes practical steps towards a stronger safety net, a contribution that speaks directly to the questions regulators across Europe are now grappling with.

Evans, J., Aixalà, M., Anderson, B. T., Brennan, W., Bremner, R., Breeksema, J. J., ... Yaden, D. B. (2025). On Minimizing Risk and Harm in the Use of Psychedelics. *Psychiatric Research and Clinical Practice*, 7(1), 4–8.

In line with OPEN's critical stance towards psychedelic research, Breeksema was one of a number of researchers led by Carolina Seybert, co-authoring a systematic review which assessed how well (or rather, how poorly) the psychological component of psychedelic treatments are reported in clinical trials, emphasising the importance of better reporting in order to better understand what these treatments actually do.

Seybert, C., Schimmers, N., Silva, L., Breeksema, J. J., Veraart, J., Bessa, B. S., ... & Oliveira-Maia, A. J. (2025). Quality of reporting on psychological interventions in psychedelic treatments: a systematic review. *The Lancet Psychiatry*, 12(1), 54–66.

Joost Breeksema also co-authored two chapters on end-of-life care and post-traumatic stress disorders, examining how psychedelic-assisted therapy might ease the psychological, emotional, and spiritual distress that can accompany a life-threatening illness. This work connects closely to OPEN's role in the PsyPal trial and its palliative-care programming throughout the year.

Bostoen, T., Tap, S., Breeksema, J., & Schoevers, R. (2025). Post-traumatic stress disorder in psychedelic research. *International Review of Neurobiology*. In *Psychedelics in Psychiatry* (International Review of Neurobiology), Vol. 181, 329–355.

Tap, S., Bostoen, T., Breeksema, J., & Schoevers, R. (2025). Psychedelics for the treatment of end-of-life distress in patients with a life-threatening disease. In *Psychedelics in Psychiatry* (International Review of Neurobiology, Vol. 181, pp. 357–393).

Finally, board members Renske Blom, Wim van den Brink, Michiel van Elk, together with Joost Breeksema jointly wrote an article explaining the Dutch Psychiatry Association Psychedelic Platform's memorandum on psychedelics in the Netherlands journal of psychiatry, aiming to enhance knowledge on psychedelics for an audience of clinical experts.

Blom, R. E., Bostoen, T., Bloemen, O. J. N., Schröder, A. E., Breeksema, J. J., van Elk, M., ... & Somers, M. (2025). Psychedelica bij de behandeling van psychiatrische aandoeningen anno 2025. *Tijdschrift voor psychiatrie*, (2025/6), 313–316.

PsyPal

PsyPal is the first clinical trial funded by the European Union dedicated to exploring the potential of psychedelic-assisted therapy. Backed by €6.5 million through the Horizon Europe framework and coordinated by University Medical Center Groningen (UMCG), it brings together a pan-European consortium of 19 partner organisations across 9 countries.

€6.5M

Horizon Europe funding

19

partner organisations

9

countries

The trial investigates whether psilocybin-assisted psychotherapy can relieve the psychological and existential distress experienced by patients with progressive, life-limiting illnesses other than cancer, specifically chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and advanced or atypical Parkinsonian disorders (APD). These forms of suffering are often overlooked in palliative care, yet they profoundly shape a patient's quality of life and experience of dying.

As an EU-funded trial in a field that has long operated at the margins of mainstream medicine, PsyPal represents a historic step towards the responsible, evidence-based integration of psychedelic care into European healthcare systems, beginning in one of its most sensitive and high-need domains.

OPEN Foundation is a core member of this consortium, and our contribution sits at the heart of how PsyPal cares for its participants and communicates its work to the wider world. OPEN is responsible for designing the project's peer-support groups, coordinating and delivering facilitator training, and collaborating with stakeholders to ensure that participants who have completed the clinical trial continue to receive high-quality, ongoing, non-denominational care, with the opportunity to integrate their experiences alongside others who have undergone similar experiences.

OPEN also leads PsyPal's communication and dissemination strategy, ensuring that the project's findings and developments reach not only academic audiences but also policymakers, healthcare leaders, and the general public. In addition, OPEN is tasked with organising a professional workshop dedicated to the intersection of palliative care and the therapeutic applications of psychedelics.

2025 saw PsyPal move from preparation into active clinical work. The project received its medical ethical authorisation, clearing the way to begin treating patients, and recruitment opened across

the participating countries. The defining milestone followed: the inclusion and dosing of the trial's first patients.

Participants will be enrolled across the four specialised clinical centres, each focusing on a single condition: ALS in Denmark, COPD in the Netherlands, MS in the Czech Republic, and atypical and advanced Parkinsonism in Portugal. Each patient participates in two therapy sessions, receiving either a high (therapeutic) or a low (non-therapeutic) dose of psilocybin in a rigorously controlled setting.

The first patient was included at UMCG in the Netherlands, with patients subsequently included and dosed at the National Institute of Mental Health in Prague (Czech Republic) and the Champalimaud Foundation in Lisbon (Portugal).

"This is a historic step. After many months of preparation, we are thrilled to begin working directly with patients."

Prof. Dr. Robert Schoevers · Head of Psychiatry at UMCG and Principal Investigator of PsyPal

With the trial underway, considerable effort went into reaching the patients who could benefit from it and the palliative care professionals who support them. To do this sensitively and across borders, recruitment and outreach materials were produced in Czech, Danish, Dutch, English, and Portuguese.

In the autumn of 2025, the PsyPal partners convened for the project's General Assembly in Lisbon (29 September – 1 October), where discussions centred on clinical trial recruitment, progress on EEG and blood-based biomarker studies, and the spiritual care dimension of the project. The assembly was accompanied by a one-day symposium hosted by the Champalimaud Foundation, "Psychedelic Therapy: From Evidence to Equity," bringing together experts, patient representatives, and members of the public, and reflecting a commitment shared across the consortium: psychedelics should not become another privilege for the few, but reach the communities that need them most.

On 27 October, OPEN organised a PsyPal event called Psychedelics in Palliative Care: Clinical and Ethical Considerations, featuring Rohini Kanniganti, MD, Anthony P. Bossis, PhD, and Sunil Aggarwal, MD, PhD.

The panel examined how psychedelic-assisted therapy might relieve the anxiety and depression faced by people with life-threatening illness, and what it would mean to bring these approaches into palliative settings responsibly, exploring the emerging clinical evidence on psilocybin, the lived realities of hospice and bereavement care, and the ethical and legal pathways shaping patient access.

Everything Else Matters

After an extended period of production and development, *Everything Else Matters: Deconstructing Psychedelic Experience*, OPEN Foundation's first feature-length documentary, co-produced with the Improbability Foundation and directed by French filmmaker Antoine Bellanger, reached audiences this year.

The one-hour film is a deep dive into the inner workings of psychedelic journeys and a timely exploration of the current state of psychedelic-assisted therapy in Europe, a field marked by rapid development, rigorous scientific investigation, and growing public interest.

The film draws on in-depth interviews with international psychiatrists, neuroscientists, therapists, and practitioners, among them Joost Brecksema, Daan Keiman, Gül Dölen, Nicholas Langlitz, Grace Blest-Hopley, and Wim van den Brink. At its centre is the question of set and setting, the mindset and the context that shape every psychedelic experience. By weaving these personal stories together with expert perspectives and cinematic storytelling, the documentary offers a glimpse into both the promise and the complexity of this evolving field.

The documentary had its premiere on 11 June 2025 at LAB111 in Amsterdam, the Netherlands, accompanied by the release of the film's trailer. The screening brought together members of OPEN's community for a special evening and marked the culmination of a project that reflects the foundation's commitment to thoughtful dialogue, scientific rigour, and public education.



Supporting the wider field

OPEN's contribution to the field extends well beyond its own programming. Throughout the year, the Foundation lent its support to conferences, summits, and training initiatives organised by others across the psychedelic community, joining them as a media and community partner to help bring their work to wider audiences.

This support reflects a conviction at the heart of OPEN's public engagement: that a stronger, more responsible field is built collectively, through open exchange and collaboration rather than in isolation. By amplifying the efforts of partner organisations across Europe and beyond, OPEN helps knit together a community of researchers, clinicians, and advocates working towards the same goal.

Events OPEN supported in 2025

27–28 Feb	Psychedelics as Medicine Conference	Reykjavík, Iceland
24 May	Uppsala Psychedelic Forum	Uppsala, Sweden
16–20 Jun	Psychedelic Science 2025	Denver, United States
26–27 Sep	Borealis Psychedelic Science Summit	Stockholm, Sweden
1 Oct	Psychedelic Therapy: From Evidence to Equity	Lisbon, Portugal
2–4 Oct	Psykedeeelit 2025: Challenging Psychedelics	Turku, Finland
2–4 Oct	Inawe Psymposium 2025	Madrid, Spain
24–25 Oct	ALPS Research Conference	Geneva, Switzerland
21–23 Nov	Psychedelic Lived Experiences Summit	Online

Whether convened in a lecture hall in Geneva, a university forum in Uppsala, or an online gathering of patients and practitioners, each of these events advances the shared work of building a rigorous, ethical, and inclusive field, and OPEN is glad to stand alongside the organisations making them happen.

Strategic advocacy and policy engagement

As Europe's regulatory and political landscape around psychedelics begins to shift, the OPEN Foundation has expanded its footprint into international policy advocacy, ensuring that rigorous science and public health frameworks guide European decision-making.

Throughout the autumn of 2025, the Foundation lent its independent expertise to high-level consultations and policy initiatives across major European institutions:

PsyPal Design Thinking Workshop

From 3 to 4 April, 2025, IESE Business School hosted a two-day workshop, bringing together many different stakeholders to generate ideas on innovative strategies for integrating psychedelic therapy into palliative care, addressing regulatory, ethical, and clinical challenges.

United Nations Office on Drugs and Crime (UNODC)

On October 2, 2025, OPEN provided expert consulting and advice to UNODC representatives Elizabeth Saenz Miranda and Ava Liang, advocating for evidence-based drug policies and ethical clinical frameworks on a global level.

European Parliament Policy Briefing

On November 4, 2025, OPEN participated in a milestone European Parliament event in Brussels co-organised by PsychedeliCare. The Foundation delivered a presentation titled "Addressing unmet medical needs with EU-funded research: The PsyPal project," briefing European policymakers on the progress and structural design of the ongoing Horizon Europe clinical trial.

PAREA Policy Launch

Also in November, OPEN participated in a major mental health innovation event at Norrskén House in Brussels. Entitled "From Lagging to Leading: Mental Health Innovation Made in Europe," the event marked the launch of the Psychedelic Access and Research Alliance (PAREA) policy paper on regulatory sandboxes. OPEN joined an esteemed panel of invited speakers, including Florence Butlen-Ducuing (formerly of the European Medicines Agency), Lowan Stewart (Axonklinikken), and Albino Oliveira-Maia (Champalimaud Foundation) to advocate for the safe, equitable implementation of these treatments across the EU.

National scientific contributions

On the domestic front, OPEN continued to bridge clinical practice and psychiatric governance, including presenting at the Dutch Association for Psychiatry's annual Spring Congress (Voorjaarscongres NVvP) in April 2025, delivering a masterclass on psychedelic therapy for the Association for Transpersonal Psychology (StVPT), among many other public appearances and presentations.

PsyPal General Assembly

In addition to policy briefings, OPEN actively participated in the PsyPal Design Thinking Workshop in Barcelona and co-coordinated the PsyPal General Assembly in Lisbon to refine spiritual care and peer-support protocols within the consortium.

PART III

Acknowledgements

III · ACKNOWLEDGEMENTS

With gratitude

The OPEN Foundation's achievements this year were the result of the collective efforts of many. We are deeply grateful to our board, team members, advisors, faculty, donors, and partners, whose expertise, trust, and commitment carried our work across education, research, advocacy, and community building.

This was a year in which long-held ambitions became reality, our educational programmes welcomed their first students, the documentary reached wider audiences, and our research collaborations moved from preparation into practice. None of it would have been possible without the people and organisations who stand alongside us.

A special acknowledgement goes to the volunteers who have given their time, energy, and skills to OPEN's work. Volunteers have been invaluable to us since our inception, and they remain indispensable so across every team and focus area, from writing for our blog and curating our newsletters, to helping convene our community events. Their passion, resilience, and generosity bring the warmth and professionalism that define OPEN's mission, and we are profoundly thankful for everything they make possible.

We are equally grateful to our collaborators and partners, among them the consortium behind the PsyPal project, the contributors and participant voices who shaped the *Everything Else Matters* documentary, and the many organisations across the field whose events we were proud to support and whose work we share with our community.

Together, we are laying the groundwork for the future of psychedelic science and care, and we look forward to continuing this work in collaboration with our growing community in the years ahead.



PART IV

Financial report

Financial position · Balance sheet · Income statement · Cash flow
statement · Valuation principles · Notes

A year of building

2025 was a year of building for the OPEN Foundation. In a year without an edition of its ICPR conference, the foundation launched the ADEPT training programme, expanded its community programmes, completed its 2025 contribution to the EU-funded PsyPal project and prepared ICPR 2026. Total income recognised in 2025 amounted to € 266,197.

The financial result for 2025 was a deficit of € 275,100. This deficit was anticipated in the 2024 annual report and should be understood in the context of several factors:

As announced in the 2024 annual report, the foundation deliberately deployed part of the reserves built up in previous years to strengthen its team and to develop and launch the ADEPT training programme. Personnel costs amounted to € 434,556 (2024: € 124,032, plus € 115,353 recorded under direct project costs), reflecting the growth of the team to eight employees at year-end.

2025 was a year without an ICPR conference edition. Ticket sales for ICPR 2026 (June 2026) started in 2025: € 191,380 of ICPR 2026 income received or invoiced in 2025 has been carried forward as deferred income, together with € 34,237 of directly related costs already paid. ICPR 2026 will therefore be reported in full in the 2026 financial statements.

The ADEPT training programme was launched, with the first cohort starting in the autumn of 2025. € 106,334 of income was recognised in 2025; € 112,102 received for the 2026 programme months is carried forward as deferred income. Development of the programme continued: € 52,402 of development costs was capitalised in 2025 (2024: € 41,000). Amortisation of the programme over three years started in 2025 (€ 20,683 in 2025).

The foundation completed its planned 2025 scope of the EU-funded PsyPal project: the € 42,767 carried forward from 2024 as work in progress was recognised as income in 2025.

€ 100,000 in donations were received in October 2025; € 25,000 was recognised as income in 2025 and € 75,000 is carried forward for the programme period up to September 2026.

With effect from 1 January 2025 the board discontinued the use of designated reserves; the balance of € 115,000 was added to the general reserve, which is freely disposable.

As of 2025 the administration is maintained on a full accrual (invoice) basis, with income and costs allocated to the period to which they relate. The 2025 figures include limited one-off transition effects, such as two years of interest income (€ 3,013 relating to 2024 and € 3,327 relating to 2025).

Total equity at the end of 2025 amounted to € 100,260 (2024: € 375,361). The foundation's liquidity position remains solid: cash and cash equivalents amounted to € 426,361 at year-end, and the largest part of current liabilities consists of income received in advance for 2026 activities rather than amounts payable.

Looking ahead, OPEN enters 2026 with strong momentum. ICPR 2026 takes place in June 2026, with € 191,380 of income already secured at the end of 2025; ADEPT Cohort 1 runs through 2026 and a second cohort is planned; and the community programmes continue. The deferred income position of € 394,837 will be recognised in 2026, and forecasts indicate a recovery of the operating result.

Financial position

Solvency

	31-12-2025	%	31-12-2024	%
Equity and reserves	100,260	18.5	375,361	83.9
Liabilities	440,516	81.5	71,935	16.1
Total assets	540,776	100	447,295	100

The solvency ratio (equity and reserves in relation to total assets) decreased from 83.9% to 18.5%. This decrease has two causes: the deployment of reserves in 2025 announced in the 2024 annual report, and the growth of the balance-sheet total through income received in advance for ICPR 2026 and the 2026 programme periods (€ 394,837), which is recorded under current liabilities. Excluding this deferred income, the solvency ratio at the end of 2025 is 68.7%. The foundation's financial position remains adequate.

Liquidity

	31-12-2025	31-12-2024
Receivables	41,696	0
Cash and cash equivalents	426,361	406,295
Current assets	468,057	406,295
Less: Current liabilities	440,516	71,935
Liquidity surplus	27,541	334,361

The liquidity surplus decreased from € 334,361 to € 27,541. This is almost entirely caused by the income received in advance for ICPR 2026 and the 2026 programme periods, which are included in current liabilities. This deferred income does not represent amounts repayable, but income to be recognised in 2026 that has largely already been received in cash. Cash and cash equivalents increased from € 406,295 to € 426,361.

1. Balance sheet as of 31 December 2025

	31-12-2025	31-12-2024
ASSETS		
Fixed assets		
Intangible fixed assets	72,719	41,000
Current assets		
Prepaid expenses	37,514	0
Accrued income	3,327	0
VAT receivable	855	0
Cash and cash equivalents	426,361	406,295
Total assets	540,776	447,295
LIABILITIES		
Equity		
General reserve	375,361	211,047
Designated reserves	0	115,000
Unappropriated result for the financial year	-275,100	49,314
Total equity	100,260	375,361
Current liabilities		
Creditors	8,847	0
Taxes and social security contributions	13,773	6,403
Holiday allowance and vacation days payable	12,673	11,303
Deferred income	394,837	42,767
Accrued expenses and other liabilities	10,387	11,461
Total current liabilities	440,516	71,935
Total liabilities	540,776	447,295

2. Income statement 2025

	2025	2024
INCOME		
Digital, subscriptions and licences	56,810	0
Training, courses and events	112,265	464,393
Grants, funds and project contributions	67,767	198,945
Financial income	6,340	518
Other income and corrections	23,015	32,696
Total income	266,197	696,552
COSTS		
Personnel costs	434,556	124,032
Professional services	14,227	9,280
Office costs	4,601	4,981
Subscriptions and software	8,811	0
Marketing costs	5,550	2,372
Programme execution costs	36,158	505,813
Amortisation and depreciation	20,683	0
Other costs and corrections	13,044	0
Financial expenses	3,666	760
Total costs	541,297	647,238
Result	-275,100	49,314
Result appropriated to the general reserve	-275,100	49,314

3. Cash flow statement 2025

	2025	2024
Cash flow from operating activities	32,877	89,732
Cash flow from investing activities	-12,811	0
Cash flow from financing activities	0	0
Increase / decrease in cash and cash equivalents	20,066	89,732
Cash and cash equivalents at 1 January	406,295	316,599
Cash and cash equivalents at 31 December	426,361	406,331

Of which, at 31 December 2025:

Bank and savings accounts	328,393	404,148
Payment provider balances	97,968	2,147

The 2025 investing cash flow concerns payments for the capitalised development of the ADEPT training programme.

The 2024 comparative figures have been restated to reconcile with the movement in cash and cash equivalents on the 2024 balance sheet.

4. Principles for valuation and determination of operating result

General

All amounts are in euros unless stated otherwise. The valuation of assets and liabilities and the determination of the result are based on historical cost. Unless stated otherwise, assets and liabilities are recorded at nominal value.

The financial statements have been prepared in accordance with Guideline 640 for Annual Reporting 'Not-for-profit Organisations'.

As of the 2025 financial year the administration is maintained on a full accrual (invoice) basis: income and costs are allocated to the period to which they relate, receivables and payables are recognised when invoiced, and amounts received in advance for future activities are recorded as deferred income. The 2024 comparative figures are taken from the 2024 financial statements.

Valuation principles for assets and liabilities

Intangible fixed assets. Development costs of the ADEPT training programme are capitalised at acquisition cost and amortised on a straight-line basis over 36 months from the month of capitalisation, with no residual value.

Tangible fixed assets. Tangible fixed assets are valued at acquisition cost, less linear depreciation calculated based on the estimated economic life. The foundation held no tangible fixed assets in 2025.

Receivables and accrued income. Receivables are valued at nominal value. A provision is made for doubtful accounts, determined based on an assessment of the individual receivables.

Cash and cash equivalents. Unless stated otherwise, cash and cash equivalents are freely available to the organisation. Cash and cash equivalents include balances held with the organisation's online payment provider.

Deferred income. Amounts received or invoiced in advance for events, programmes and projects that take place after the balance-sheet date are recorded as deferred income under current liabilities and recognised as income in the period in which the activities take place.

Principles for the determination of results

Revenue. Income from events, training programmes, projects, grants and donations is recognised in the year in which the related activities take place. Receipts for activities after the balance-sheet date are recorded as deferred income. Contributions and grants that relate to a specific period are recognised over that period.

Operating expenses. Operating expenses are determined in accordance with the aforementioned valuation principles and allocated to the reporting year to which they relate. Losses are recognised in the year in which they become foreseeable. Costs directly attributable to events and programmes taking place after the balance-sheet date are carried forward as prepaid expenses.

Principles of the cash flow statement

The cash flow statement is prepared using the direct method. The cash and cash equivalents in the statement consist of freely available bank and savings balances and balances held with the organisation's online payment provider. Cash flows in foreign currencies are converted using an estimated average exchange rate.

5. Notes to the balance sheet

Fixed assets — Intangible fixed assets

The movements in intangible fixed assets in 2025 are as follows:

	ADEPT DEVELOPMENT COSTS
1 January 2025	
Acquisition value	41,000
Less: Accumulated amortisation	0
Book value	41,000
Movements in 2025	
Capitalised development costs	52,402
Amortisation in the financial year	-20,683
31 December 2025	
Acquisition value	93,402
Less: Accumulated amortisation	-20,683
Book value	72,719

The capitalised amounts relate to the development of the ADEPT training programme (lectures, video production, programme development and accreditation). The applied amortisation period is 36 months (33.3% per year), starting in the month of capitalisation.

The foundation held no tangible fixed assets in 2025.

Current assets — Receivables

	31-12-2025	31-12-2024
Prepaid expenses — ICPR 2026 direct costs carried forward	34,237	0
Prepaid expenses — other	3,277	0
Accrued income (interest 2025, received January 2026)	3,327	0
VAT receivable	855	0
Balance as of 31 December	41,696	0

All trade receivables outstanding during the year were settled; the debtors balance at 31 December 2025 is nil (31 December 2024: nil).

Cash and cash equivalents

	31-12-2025	31-12-2024
Current account	75,437	104,184
Savings account	253,013	300,000
Credit card	-57	-35
Payment provider balances	97,968	2,147
Balance as of 31 December	426,361	406,295

Cash and cash equivalents are freely available to the organisation. The payment provider balances are amounts held by the online payment provider pending payout to the bank accounts and largely relate to ICPR 2026 ticket sales.

Equity

FREELY DISPOSABLE EQUITY	2025	2024
Balance as of 1 January	260,361	211,047
From designated reserves	115,000	0
From allocation of result	-275,100	49,314
Balance as of 31 December	100,260	260,361

With effect from 1 January 2025 the board discontinued the use of designated reserves. The designated reserves at 31 December 2024 (€ 115,000) were added to the general reserve as of 1 January 2025, shown above as 'From designated reserves'; the entire equity is freely disposable. The 2025 result is charged to the general reserve.

Current liabilities — Deferred income

	31-12-2025
ICPR 2026 — conference	175,423
ADEPT Academy	128,457
Donations (October 2025 – September 2026)	75,000
ICPR 2026 — workshops	15,957
Balance as of 31 December	394,837

Deferred income concerns amounts received or invoiced in 2025 for activities taking place in 2026: ICPR 2026 ticket sales and sponsorships, the 2026 months of the ADEPT programme, and the remaining period of the Donations. These amounts are recognised as income in 2026 (2024: € 42,767, the PayPal project position recognised in 2025).

Current liabilities — Taxes and social security contributions

	31-12-2025	31-12-2024
Payroll tax and social security contributions (December)	10,296	6,403
VAT payable (net)	3,477	0
Balance as of 31 December	13,773	6,403

Current liabilities — Other liabilities and accrued expenses

	31-12-2025	31-12-2024
Holiday allowance and vacation days payable	12,673	11,303
Accrued expenses and other liabilities	10,387	11,461
Balance as of 31 December	23,059	22,765

The amounts carried forward from 2024 were largely settled or released during 2025. The 31 December 2025 position concerns invoices and costs relating to 2025 that were received or settled after year-end.

6. Notes to the statement of income

Income

The income recognised in 2025 is as follows:

	2025
Digital, subscriptions and licences	
Licence income	15,511
Online platform and memberships	41,299
Total digital, subscriptions and licences	56,810
Training, courses and events	
Training programmes and courses	110,806
Participant contributions	1,459
Total training, courses and events	112,265
Grants, funds and project contributions	
EU and international grants	42,767
Contributions from funds and foundations	25,000
Total grants, funds and project contributions	67,767
Financial income	
Interest received on bank and savings accounts	6,340
Total financial income	6,340
Other income and corrections	
Other income	124
Prior-year corrections (income)	22,891
Total other income and corrections	23,015
Total income	266,197

By programme, income breaks down as follows:

	2025	%
ADEPT Academy	110,807	41.6
Community — events	59,878	22.5
PsyPal	42,767	16.1
General and unallocated (incl. donations and interest)	34,776	13.1
Everything Else Matters (film programme)	15,511	5.8
Community — workshops	1,459	0.5
ICPR 2024 (residual)	1,000	0.4
Total income	266,197	100

The prior-year corrections within 'Other income and corrections' mainly concern 2024 income received in 2025 that was not yet recognised under the previous cash-basis administration (one-off transition effect).

Personnel costs

	2025
Gross wages and salaries	251,270
Social security and pension contributions	72,108
Other personnel expenses	111,178
Total personnel costs	434,556

Total personnel costs in 2025 amounted to € 434,556 (2024: € 124,032, plus € 115,353 recorded under direct project costs for ICPR 2024). The increase reflects the deliberate strengthening of the team announced in the 2024 annual report.

Furthermore, the figures are not fully comparable with 2024: as of 2025 the administration recognises the full accrual cost of employment (employer social security contributions including the income-dependent healthcare insurance contribution (Zvw), the holiday-allowance accrual and the December payroll taxes), whereas the 2024 administration was kept on a cash basis.

Nine employees were employed in the course of 2025, of whom eight as at 31 December 2025. The average number of personnel in 2025 was 4.45 FTE.

Remuneration — Directors and board members 2025

	REMUNERATION	EXPENSE ALLOWANCES	PENSION PROVISION
J.J. Breeksema, Director (entire 2025)	48,102	0	3,428
T. Spijkers, Director (entire 2025)	37,676	0	1,926

The members of the board received no remuneration in 2025.

Professional services

Accounting and administration costs	5,264
Legal costs	2,895
Consultancy and advisory	5,650
Insurance	418
Total	14,227

Office costs

Rent	3,458
Office supplies	299
Printing, postage and freight	845
Total	4,601

Subscriptions and software

Software	8,811
Total	8,811

Marketing costs

Advertising	4,013
Representation and catering	1,059
Business gifts	297
Photography and videography	182
Total	5,550

Programme execution costs

Venue costs	6,758
Facilities	770
Materials	915
Production	25,654
Catering	2,062
Total programme execution costs	36,158

Programme execution costs concern venues, facilities, materials and production for the 2025 programmes (ADEPT, community events and the film programme). Direct costs already paid for ICPR 2026 are carried forward as prepaid expenses and are not included here.

Amortisation and depreciation

Amortisation of intangible fixed assets	20,683
Total amortisation and depreciation	20,683

Amortisation concerns the capitalised development costs of the ADEPT training programme (36 months, straight-line).

Other costs and corrections

Prior-year corrections (costs)	11,744
Other exceptional costs	1,300
Total other costs and corrections	13,044

Other costs and corrections concern costs relating to earlier years that were recognised in 2025, together with a number of incidental items.

Financial income and expenses

Financial income	
Interest received on bank and savings accounts	6,340
Financial expenses	
Interest expenses	318
Bank charges	3,348
Total financial expenses	3,666
Balance of financial income and expenses	2,674

Interest received in 2025 includes € 3,013 of interest relating to 2024 that was received in 2025 (one-off transition effect of the change to the accrual basis) and € 3,327 of interest relating to 2025.



Approval of the financial statements

Amsterdam, 22 June 2026

CHAIR OF THE BOARD	W. van den Brink
--------------------	-------------------------

TREASURER	M. van Elk
-----------	-------------------

SECRETARY	P.P.R.W. Pisters
-----------	-------------------------

BOARD MEMBER	E. Krediet
--------------	-------------------

BOARD MEMBER	R.E. Blom-Nivard
--------------	-------------------------

Signed and approved by the board on 22 June 2026

LOOKING FORWARD

Into 2026

With the internal infrastructure solidified and the financial baseline stabilised, the Foundation enters 2026 with clear fiscal governance and optimised resource allocation.

Our strategic pivot towards robust vocational education via ADEPT and Foundations, paired with prestigious international research like the PsyPal project, ensures that the organisation remains both financially sustainable and deeply impactful as Europe's psychedelic ecosystem evolves.

Joost — The OPEN Foundation

Amsterdam, The Netherlands

Registered Ref: Chamber of Commerce (KVK) No. 34274712